BioSpace News Archive

Rocket Pharmaceuticals to Hold Webcast for Investors Highlighting Data Presented at the 62 nd American Society of Hematology Annual Meeting — Rocket Management to Discuss Data Updates from the Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I) and Pyruvate Kinase Deficiency (PKD) Programs —

CytoSorbents Corporation announces the launch of its international fundraising campaign to raise $100,000 to benefit the global, not-for-profit humanitarian organization, CARE USA.

Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced the appointment of Paolo Pucci as a new Board Director.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will participate in a virtual fireside chat at the Guggenheim Digital Health Summit on December 8, 2020 at 9:45 a.m. Eastern Time. Investors may access a live audio webcast

Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to cancer detection, and University of Chicago today announce the publication of a genome-wide 5-hydroxymethylcytosine (5hmC) map across multiple human tissue types.

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its subsidiary, Athenex Pharmaceutical Division (APD), has launched Liquid, Ready-To-Dilute Cyclophosphamide

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors that will enter a pivotal Phase 3 study CRIMSON 1 this m

Abbott (NYSE:ABT) today announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval by Health Canada for adults and children (4 and older) with diabetes.

Thorne Research, Inc., yesterday filed a petition for inter partes review at the U.S. Patent Trial and Appeal Board to challenge Claim 2 of U.S. Patent No. 8,383,086, which relates to pharmaceutical compositions of nicotinamide riboside.

APVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the Treatment of Prostate Cancer